C. Porta

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

C. Porta, G. Ceresoli, L. Boni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.

R. Motzer, H. Desilva, N. Tannir, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

R. Motzer, B. Escudier, A. Shah, 2024, ESMO open.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

B. Escudier, S. Oosting, S. Bracarda, 2020 .